|
Report Date : |
05.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
ZYDUS WELLNESS LIMITED |
|
|
|
|
Registered
Office : |
“Zydus Tower”, Satellite Cross Roads, Sarkhej-Gandhinagar Highway,
Ahmedabad – 380015, Gujarat |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2013 |
|
|
|
|
Date of
Incorporation : |
01.11.1994 |
|
|
|
|
Com. Reg. No.: |
023490 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.390.700 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
L15201GJ1994PLC023490 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
AHMC00196A |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACC7740G |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The Company’s Shares are Listed on
the Stock Exchange. |
|
|
|
|
Line of Business
: |
Development,
Production, Marketing and Distribution of Health and Wellness Products. |
|
|
|
|
No. of Employees
: |
Information denied by management. |
RATING & COMMENTS
|
MIRA’s Rating : |
A (63) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 10300000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having a fine
track record. Even though there appears some dip in the sales during 2013, the
profit margin has improved. Financial position of the company appears to be
sound. Trade relations are reported as trustworthy. Business is active.
Payments are reported to be regular and as per commitments. The company can be considered good for business dealings at usual
trade terms and conditions. |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
INDIAN ECONOMIC OVERVIEW
We are living in a
world where volatility and uncertainty have become the New Normal. We saw
a change of government in countries like Tunisia, Egypt, Libya and Vietnam.
Once powerful countries in Europe are now fighting for bankruptcy. We have
taken growth in the developing part of the world for granted but economic
growth in China and India has begun to slow. Companies that were synonymous
with their product categories just a few years ago are now no longer in
existence. Kodak, the inventor of the digital camera had to wind up its
operations, HMV, the British entertainment retailing company and Borders, once
the second largest bookstore have shut down due to their inability to evolve
their business models with the changing time. Readers’ Digest, Thomson Register
are no more !
There is another
megatrend happening. The World order is changing as economic power shifts from
West to East. According to McKinsey study, it took Britain more than 100 years
to double its economic output per person during its industrial revolution and
the US later took more than 50 years to do the same. More than a century later,
China and India have doubled their GDP per capital in 12 and 18 years
respectively. By 2020, emerging Asia will become the world’s largest consuming
block, overtaking North America.
The years after the
outbreak of the global financial crisis, the world economy continues to remain
fragile. The Indian economy demonstrated remarkable resilience in the initial
years of the contagion but finally lost ground last year. GDP growth slowed
down. Currency has been weakening. There is a marked deceleration in
agriculture, industry and services. Dampening sentiment led to a cut-back in
investment as well as private consumption expenditure. Inflation remained
at high levels fuelled by the pressure from the food and fuel sectors. The
large fiscal and current account deficit s continued to cause grave concern. It
is imperative that India regains its growth trajectory of 8-9 % sooner than
later. This is crucially important given the need to create gainful livelihood
opportunities for the millions living in poverty as also the large contingent
of young people joining the job market every year.
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION DECLINED
MANAGEMENT NON CO-OPERATIVE.
LOCATIONS
|
Registered/ Corporate Office : |
“Zydus Tower”, Satellite Cross Roads, Sarkhej-Gandhinagar Highway,
Ahmedabad – 380015, Gujarat, India |
|
Tel. No.: |
91-79-26868100 (20 Lines) |
|
Fax No.: |
91-79-26862253 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory : |
7A, 7B and 8, Saket Industrial Estate, Sarkhej Bavla Road, Village
Moraiya, Taluka Sanand, District Ahmedabad, Gujarat, India |
DIRECTORS
(AS ON 31.03.2013)
|
Name : |
Mr. Pankaj R Patel |
|
Designation : |
Chairman |
|
|
|
|
Name : |
Elkana N. Ezekiel |
|
Designation : |
Managing Directors |
|
|
|
|
Name : |
Mr. H Dhanrajgir |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Mukesh M Patel |
|
Designation : |
Director |
|
Date of Birth/ Age : |
59 years |
|
Date of Appointment : |
27.07.2006 |
|
|
|
|
Name : |
Dr. B M Hegde |
|
Designation : |
Director |
|
|
|
|
Name : |
Prof. Indiraben J. Parikh |
|
Designation : |
Director |
|
Date of Birth/ Age : |
69 years |
|
Date of Appointment : |
29.07.2009 |
|
|
|
|
Name : |
Mr. Ganesh Nayak |
|
Designation : |
Director |
|
|
|
|
Name : |
Dr. Sharvil P Patel |
|
Designation : |
Director |
|
Date of Birth/ Age : |
34 years |
|
Date of Appointment : |
27.04.2009 |
KEY EXECUTIVES
|
Name : |
Mr. Amit B Jain |
|
Designation : |
Chief Financial Officer |
|
|
|
|
Name : |
Mr. Dhaval N Soni |
|
Designation : |
Company Secretary |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
(AS ON 30.06.2013)
|
Category of
Shareholder |
Total No. of Shares |
Total Shareholding as a % of Total No. of Shares |
|
|
|
|
|
(A) Shareholding
of Promoter and Promoter Group |
|
|
|
|
|
|
|
|
179292 |
0.46 |
|
|
28164395 |
72.08 |
|
|
28343687 |
72.54 |
|
|
|
|
|
|
|
|
|
Total
shareholding of Promoter and Promoter Group (A) |
28343687 |
72.54 |
|
|
|
|
|
(B) Public
Shareholding |
|
|
|
|
|
|
|
|
2212504 |
5.66 |
|
|
3826 |
0.01 |
|
|
2023527 |
5.18 |
|
|
1999737 |
5.12 |
|
|
0 |
0.00 |
|
|
6239594 |
15.97 |
|
|
|
|
|
|
|
|
|
|
1026816 |
2.63 |
|
|
|
|
|
|
|
|
|
|
2727569 |
6.98 |
|
|
460244 |
1.18 |
|
|
|
|
|
|
274179 |
0.70 |
|
|
207127 |
0.53 |
|
|
48826 |
0.12 |
|
|
18226 |
0.05 |
|
|
4488808 |
11.49 |
|
|
|
|
|
Total Public
shareholding (B) |
10728402 |
27.46 |
|
|
|
|
|
Total (A)+(B) |
39072089 |
100.00 |
|
|
|
|
|
(C) Shares held
by Custodians and against which Depository Receipts have been issued |
|
|
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
|
|
|
|
Total
(A)+(B)+(C) |
39072089 |
100.00 |
Shareholding
of securities (including shares, warrants, convertible securities) of persons
belonging to the category Promoter and Promoter Group
|
S. No. |
Name of the Shareholder |
Details of Shares held |
|
|
No. of Shares held |
As a % of grand total (A)+(B)+(C) |
||
|
1 |
Cadila Healthcare Limited |
2,74,43,274 |
70.24 |
|
2 |
Zydus Animal Health Limited |
7,20,481 |
1.84 |
|
3 |
Zydus Family Trust |
1,74,495 |
0.45 |
|
4 |
Pripan Investment Private Limited |
640 |
0.00 |
|
5 |
Shivani Pankajbhai Patel |
533 |
0.00 |
|
6 |
Pankaj Ramanbhai Patel |
533 |
0.00 |
|
7 |
Pankaj Ramanbhai Patel |
533 |
0.00 |
|
8 |
Pankaj Ramanbhai Patel HUF |
533 |
0.00 |
|
9 |
Pankaj Ramanbhai Patel |
533 |
0.00 |
|
10 |
Pritiben Ramanbhai Patel |
533 |
0.00 |
|
11 |
Taraben Ramanbhai Patel |
533 |
0.00 |
|
12 |
Ramanbhai B Patel HUF |
533 |
0.00 |
|
13 |
Sharvil Pankajbhai Patel |
533 |
0.00 |
|
|
Total |
2,83,43,687 |
72.54 |
(*) The term encumbrance has the same meaning as assigned to it in
regulation 28(3) of the SAST Regulations, 2011.
Shareholding of
securities (including shares, warrants, convertible securities) of persons
belonging to the category Public and holding more than 1% of the total number
of shares
|
S. No. |
Name of the Shareholder |
No. of Shares held |
Shares as % of Total No. of Shares |
|
|
1 |
Life Insurance Corporation of India |
1730377 |
4.43 |
|
|
2 |
Baring India Pvt Equity Fund III Listed
Investment Limited |
767919 |
1.97 |
|
|
3 |
HDFC Trustee Company Limited - HDFC
Prudence |
578103 |
1.48 |
|
|
4 |
Reliance Capital Trustee Company Limited |
560645 |
1.43 |
|
|
5 |
HDFC Trustee Company Limited -HDFC Mutual
Fund |
500000 |
1.28 |
|
|
|
Total |
4137044 |
10.59 |
BUSINESS DETAILS
|
Line of Business : |
Development,
Production, Marketing and Distribution of Health and Wellness Products. |
GENERAL INFORMATION
|
No. of Employees : |
Information denied by management. |
|
|
|
|
Bankers : |
· Bank of Baroda Ashram Road Branch, Ahmedabad, Gujarat, India · BNP Paribas Ahmedabad Branch, Ahmedabad, Gujarat, India |
|
|
|
|
Facilities : |
-- |
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Manubhai and Company Chartered Accountants |
|
|
|
|
Holding Company : |
· Cadila Healthcare Limited |
|
|
|
|
Partnership
Firm : |
· Zydus Wellness - Sikkim |
|
|
|
|
Fellow Subsidiaries : |
·
Dialforhealth India Limited ·
Dialforhealth Unity Limited ·
Dialforhealth Greencross Limited ·
German Remedies Limited ·
Zydus Pharmaceuticals Limited ·
Zydus Animal Health Limited ·
Liva Healthcare Limited · Zydus Technologies Limited · Biochem Pharmaceutical Industries Limited ·
Zydus Healthcare, a Partnership Firm ·
Zydus Lanka (Private) Limited [Sri Lanka] ·
Zydus Pharmaceuticals (USA) Inc. [USA] ·
Nesher Pharmaceuticals (USA) LLC [USA] ·
Zydus Healthcare (USA) LLC [USA] ·
Zydus Noveltech Inc. [USA] ·
Hereon Pharmaceuticals LLC [USA] ·
Zydus Healthcare S.A. (Pty) Limited [South Africa] ·
Simayla Pharmaceuticals (Pty) Limited [South Africa] ·
Script Management Services (Pty) Limited [South Africa] ·
Zydus Nikkho Farmaceutica Ltda. [Brazil] ·
Zydus Pharma Japan Company Limited [Japan] · Laboratories Combix S.L. [Spain] ·
Zydus
International Private Limited [Ireland] ·
Zydus
Netherlands B.V. [the Netherlands] ·
Zydus France,
SAS [France] ·
Etna Biotech
S.R.L. [Italy] ·
ZAHL Europe
B.V. [the Netherlands] ·
Zydus
Pharmaceuticals Mexico SA De CV, [Mexico] ·
Zydus
Pharmaceuticals Mexico Services Company SA De CV.[Mexico] ·
ZAHL B.V. [the
Netherlands] ·
Bremer Pharma
GmbH [Germany] |
CAPITAL STRUCTURE
(AS ON 31.03.2013)
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
45000000 |
Equity Shares |
Rs.10/- each |
Rs.450.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
39072089 |
Equity Shares |
Rs.10/- each |
Rs.390.720
Millions |
|
|
|
|
|
NOTES:
A. There is no change in
the number of shares as at the beginning and the end of the year.
|
Number of shares at the
beginning and at the end of the year. |
39072089 |
B. The
Company has only one class of shares i.e. equity shares. All equity shares
carry equal rights with respect to voting and dividend. In the event of liquidation
of the Company, the equity shareholders shall be entitled to proportionate
share of their holding in the assets remaining after distribution of all
preferential amounts.
|
C. Details of Shareholders holding more
than 5% of equity shares of Rs. 10/- each, fully paid-up: |
|
|
Cadila Healthcare Limited |
|
|
Number of Shares |
27443274 |
|
% to total share holding |
70.24% |
|
|
|
|
D. Number of Shares held by holding
company and its subsidiary company: |
|
|
Cadila Healthcare
Limited [Holding company] |
27443274 |
|
Zydus
Animal Health Limited [Fellow subsidiary] |
720481 |
E. The
Company has issued 3,34,96,989 equity shares of Rs.10/-each fully paid-up in the
ratio of 04:15 pursuant to the Composite Scheme of Arrangement between the
Company and Cadila Healthcare Limited, Zydus Hospitals and Medical Research
Private Limited, their respective shareholders and creditors approved by
Hon'ble High Court of Gujarat at Ahmedabad, vide order dated October 23, 2008
in the year 2008-09.
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
390.700 |
390.700 |
390.700 |
|
(b) Reserves & Surplus |
2174.700 |
1477.900 |
1028.200 |
|
(c) Money received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1)+(2) |
2565.400 |
1868.600 |
1418.900 |
|
|
|
|
|
|
(3) Non-Current
Liabilities |
|
|
|
|
(a) long-term borrowings |
0.000 |
0.000 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
21.900 |
18.500 |
11.100 |
|
(c) Other long
term liabilities |
3.700 |
6.000 |
4.000 |
|
(d) long-term
provisions |
0.200 |
0.100 |
0.200 |
|
Total Non-current
Liabilities (3) |
25.800 |
24.600 |
15.300 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a)
Short term borrowings |
0.000 |
0.000 |
0.000 |
|
(b)
Trade payables |
152.200 |
244.700 |
347.100 |
|
(c) Other
current liabilities |
34.800 |
39.200 |
83.700 |
|
(d) Short-term
provisions |
277.200 |
229.500 |
191.300 |
|
Total Current
Liabilities (4) |
464.200 |
513.400 |
622.100 |
|
|
|
|
|
|
TOTAL |
3055.400 |
2406.600 |
2056.300 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a)
Fixed Assets |
|
|
|
|
(i)
Tangible assets |
285.100 |
298.800 |
302.800 |
|
(ii)
Intangible Assets |
228.700 |
228.900 |
229.100 |
|
(iii) Capital
work-in-progress |
0.000 |
0.000 |
3.100 |
|
(iv)
Intangible assets under development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
24.500 |
24.500 |
24.500 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
33.900 |
34.900 |
11.600 |
|
(e) Other
Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total Non-Current
Assets |
572.200 |
587.100 |
571.100 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a)
Current investments |
932.800 |
452.600 |
372.500 |
|
(b)
Inventories |
67.400 |
60.400 |
175.000 |
|
(c)
Trade receivables |
4.600 |
3.600 |
11.700 |
|
(d) Cash
and cash equivalents |
1461.500 |
1271.700 |
877.600 |
|
(e) Short-term
loans and advances |
15.600 |
28.500 |
38.200 |
|
(f)
Other current assets |
1.300 |
2.700 |
10.200 |
|
Total
Current Assets |
2483.200 |
1819.500 |
1485.200 |
|
|
|
|
|
|
TOTAL |
3055.400 |
2406.600 |
2056.300 |
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
Net Revenue from Operations |
2130.100 |
2535.900 |
3363.700 |
|
|
|
Other Income |
138.900 |
88.100 |
72.100 |
|
|
|
TOTAL |
2269.000 |
2624.000 |
3435.800 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of Materials Consumed |
572.900 |
574.900 |
498.500 |
|
|
|
Purchases of Stock in Trade |
72.700 |
236.600 |
749.300 |
|
|
|
Changes in Inventories of Finished Goods, Works in Progress and Stock
in Trade |
(0.700) |
116.500 |
(45.800) |
|
|
|
Employee Benefits Expenses |
119.600 |
100.700 |
183.000 |
|
|
|
Other Expenses |
487.500 |
786.200 |
1136.300 |
|
|
|
TOTAL |
1252.000 |
1814.900 |
2521.300 |
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION |
1017.000 |
809.100 |
914.500 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
23.700 |
23.000 |
14.900 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
993.300 |
786.100 |
899.600 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
22.200 |
109.300 |
304.800 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX |
971.100 |
676.800 |
594.800 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
0.200 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Stores & Spares |
1.900 |
0.000 |
0.400 |
|
|
|
Capital Goods |
0.000 |
4.200 |
54.700 |
|
|
|
Others (Repairs to Machinery) |
0.000 |
0.100 |
0.000 |
|
|
TOTAL IMPORTS |
1.900 |
4.300 |
55.100 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
24.85 |
17.32 |
15.22 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
PAT / Total Income |
(%) |
42.80
|
25.79 |
17.31 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
46.63
|
30.99 |
26.74 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
32.77
|
33.00 |
44.34 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.39
|
0.42 |
0.63 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
0.00
|
0.00 |
0.00 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
5.35
|
3.54 |
2.39 |
LOCAL AGENCY FURTHER INFORMATION
CURRENT MATURITY
OF LONG TERM BORROWINGS DETAIL: NOT AVAILABLE
|
Sr. No. |
Check List by Info Agents |
Available in Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
----- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
----- |
|
22] |
Litigations that the firm / promoter
involved in |
Yes |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
No |
|
25] |
Conduct of the banking account |
----- |
|
26] |
Buyer visit details |
----- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
Date of Birth of
Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director, if
available |
No |
|
33] |
Voter ID No of Proprietor/Partner/Director,
if available |
No |
|
34] |
External Agency Rating, if available |
No |
-----------------------------------------------------------------------------------------------------------------------------
IN THE HIGH COURT OF DELHI AT NEW DELHI
CS (OS) 2268/2010
ALTICOR INC AND ANR….
Plaintiffs
Through: Counsel for the plaintiffs (appearance not given)
versus
ZYDUS WELLNESS LTD and ANR…. Defendants
Through: Mr. Neeraj
Kishan Kaul, Sr. Adv. with Ms. Bitika Sharma and Ms. Kamna Nagpal, Advs.
CORAM:
HON'BLE MR. JUSTICE RAJIV SAHAI ENDLAW
ORDER
29.04.2013
IA No.6812/2013 (of the defendants u/S 124 of the Trade Marks Act, 1999)
1. It is inter alia the plea of the defendants in the written statement that
the plaintiffs are not using the Trademark for all the classes for which
registration has been obtained and has been granted registration in the wrong
classes.
2. It has been enquired from the senior counsel for the defendants / applicants
whether the same amounts to the registration of the plaintiffs? Trademark being
invalid within the meaning of Section 124(1) of the Act.
CS (OS) 2268/2010 Page 1 of 2
3. The senior counsel for
the defendants / applicants has invited attention to Section 47 and Section 57(2)
of the Act to contend that the plea of the Trademark remaining wrongfully on
the register despite non use is also a plea of invalidity within the meaning of
Section 124(1) and thus, the Section would be attracted.
4. The counsel for the plaintiffs / non applicants states that notice of the
application be issued and a reply thereto shall be filed.
5. Though the plaintiffs ought to have been ready to argue the application but since time for filing additional documents was given, issue notice. Notice is accepted by the counsel for the plaintiffs / non applicants. Reply be filed within four weeks. Rejoinder within four weeks thereafter. The time for filing the additional documents is also extended by six weeks.
6. List on 6th August, 2013.
RAJIV SAHAI ENDLAW, J
APRIL 29, 2013\
CS(OS) 2268/2010 Page 2 of 2
35$
-----------------------------------------------------------------------------------------------------------------------------
MANAGEMENT DISCUSSION AND ANALYSIS 2012-2013
OVERVIEW – YEAR 2012-13
STATE OF ECONOMY, INDUSTRY AND THEIR BUSINESS
The
globalization of India has given rise to new opportunities but it has also
brought with it new challenges. It means that the global economy can no longer
be viewed from a spectator's standpoint. What happens globally has larger
implications for India. The global economic situation remains far from stable
and this is reflected in the prospects for India's growth. Most of the
macro-economic data for India released recently indicates signs of moderation.
The IIP growth has been languishing and growth rate of exports has been in the
negative terrain for many months. Nonetheless, some key policy announcements
undertaken last year did uplift the confidence levels and created optimism with
regard to the future. However, the pickup in investment activity especially
from foreign investors remains subdued.
As per the
latest Advanced Estimates (AE) of the Central Statistics Office (CSO), growth
in GDP at factor cost at constant prices was estimated at 5 per cent in 2012-13
as compared to the revised growth of 6.2 per cent in 2011-12. Index of
Industrial Production ("IIP"), which is considered to be the
barometer of Indian industrial growth, is expected to have grown by 0.9% during
April - February 2012-13 vs. 3.5% growth during the same period last year. The
average Wholesale Price Index (WPI) inflation rate for the last 12 months
(April 12 to March 13) was 7.3% as compared to 8.9% during the corresponding
period in 2011-12. (Source: Monthly Economic Report, March 2013 as published by
the Ministry of Finance, Government of India).
The Indian
health and wellness industry is set to double by 2015 if current trends
continue, a joint report by industry body FICCI and advisory firm
PricewaterhouseCoopers (PwC) said. At present, the sector is estimated at Rs.
590 billion and is growing at a CAGR of 18-20 per cent. Though traditional
products continue to dominate the market at 60 per cent, consumer awareness of
new forms of wellness products and services such as fortified foods, dietary
supplements, cosmetic treatments and rejuvenation therapies is growing. The
report also highlights that tier 2 and tier 3 cities offer headroom for growth
but add that these markets require investments and long-term focus. "Many
wellness segments extend beyond traditional gender boundaries traditional
products and services continue to appeal to the Indian consumer, but these now
need to meet modern sensibilities" according to the report.
The report
further mentions that brands are becoming increasingly relevant for Indian
consumers and that companies need to invest in communicating with consumers to
remain salient. "Consumers are increasingly placing a high premium on
their time, so wellness players have started bundling convenience along with
health and beauty benefits" it says. It predicts that mainstream and
generic wellness concepts in India will continue to dominate, while emerging
niche categories are likely to result in new opportunities. Online channels too
are expected to grow in relevance as a medium for interaction with consumers.
Increasing
health awareness among Indian consumers due to rising media penetration is also
helping the sector to grow. "Given high disposable incomes, consumers are
taking into account health considerations as part of their purchasing
decisions, with preventive care gaining more prominence over a curative
approach to disease management", said Sandeep Ahuja, Chairman, FICCI
National Wellness Committee. The FICCI-PwC report further adds that the per capita
spend on wellness has jumped from Rs 300 in 2008 to over Rs 480, last year.
Company
has been a niche and significant player in this growing market with its
portfolio of health care brands viz. Sugar Free, Everyuth, Nutralite and Actilife.
These brands have been driving, contributing and participating in growing the
health and wellness market in this country.
The year
has witnessed a strong performance from the company. During 2012-13, the
Company recorded gross sales of Rs.4100 Mio. up by 19% and a net profit of
Rs.971 Mio., up by 43.5% on a consolidated basis. The company took several
initiatives during the year to strengthen its brands and its leadership
position. These are outlined below:
SUGAR FREE
- INDIA'S LARGEST SELLING LOW CALORIE SWEETENER
Sugar Free
has maintained its leading position in the low calorie sugar substitute
category with a market share of more than 90% as of March 31, 2013. Both Sugar
Free Gold, an aspartame based sweetener and Sugar Free Natura, which is
sucralose based, have maintained their top slots. With this strong market
share, Sugar Free continues to be the driving force for overall category
growth.
The
brand's comeback to high growth trajectory was driven by strong marketing
support in the form of a new theme campaign with endorsement by a new celebrity
and integrating all products on one platform. The brand's multi-product
presence with Sugar Free Gold and Natura across different product formats like
pellets, powders and drops gives the consumer a broad basket of choices. While
there have been new entrants into the category, the strength of the brand's
equity has allowed an enhanced market share and a prominent retail presence.
Given the low household penetration levels of sugar substitutes, the Company's
focus will be category development in the future as the route to generating
strong growth.
EVERYUTH -
CELEBRATING YOUTH!
The
everyuth range of skin-care products maintained its leadership position in the
scrubs and peel-off category while the face wash category continued to
experience aggressive competition.
Reflecting
the aspirations of the modern Indian consumer and with a view to being relevant
and contemporary, the Company re-launched the brand with new exciting
packaging, improved formulations for superior performance and aesthetics and a
powerful new marketing programme. A new celebrity has been signed on as the
brand ambassador who now features in all advertising, point of sale and outdoor
communication. The company also launched new variants of face washes (Radiant
Fairness, Pollution Defense, Aloe and Skin Balancing Grape), two new variants
of Scrubs (Radiant Fairness Strawberry Scrub and Foot Scrub) and re-launched
the everyuth Menz line with new modern packaging and a high technology whitening
cream. As part of a broader distribution expansion drive, the Company has also
entered the soap category and launched its first range of transparent soaps in
Lemon, Fruit and Neem variants. Plans are in place to expand the product
portfolio further and improve distribution reach backed by strong advertising
and promotional support to keep everyuth on a high paced growth going forward.
NUTRALITE
- 'HEALTH FIRST, TASTE ALWAYS'
The table
spread category has recorded subdued growth rates throughout the year. There
have also been multiple launches from low priced competitors with a focus on
the price conscious institutional customers. Despite this, Nutralite has
maintained its dominant position in margarine category through a commitment to
quality and service. In retail, the Company has expanded its product portfolio
with the launch of a premium variant, Nutralite with Omega 3. This launch has
strengthened the health positioning of the brand and created a platform for
future growth. The launch has been backed by strong advertising and trade
activations resulting in a positive consumer response. It was voted 'Product of
the Year 2013' based on an independent survey conducted amongst 18000 consumers
in India undertaken by global research agency AC Nielsen. This prestigious
award is reserved for products which have excelled in innovation and in
delivering consumer satisfaction. An additional flavor variant with cheese has
also been added to the portfolio. Both the products are free of trans fats and
are fortified with Vitamins A, D and E.
In the
year ahead, the Company expects to continue focusing on expanding the product
portfolio and building an awareness of the health benefits of the brand with a
view to grow the consumer base.
ACTILIFE -
NUTRITION FOR ADULTS
Actilife
was launched in 2011 as a nutritional milk additive for adults. To create this
new concept the Company has been investing in education through advertising,
sampling programs and in-store activations. As with any new idea, the lead time
for its adoption is often fairly long and the Company is diligent in its
approach while refining the marketing support programs to achieve business
goals.
As a
strategy, the Company is also looking at line extensions aggressively across the
different categories where it competes. All brands in the portfolio have strong
equity with consumers and ready acceptance in the trade. This allows the
Company to bring innovative new products to the market and drive growth by
leveraging its strong health care heritage.
With a
continued focus on strengthening its existing portfolio, expanding distribution
to reach a wider consumer base and launch of innovative products in the
wellness domain, the Company is confident of achieving its long term goals and
bringing wellness to the lives of every Indian.
COMPANY OVERVIEW:
The
Company was incorporated on November 1,
1994 and operates as an integrated consumer company with business encompassing
the entire value chain in the development, production, marketing and
distribution of health and wellness products. The product portfolio of the
Company includes brands like Sugar free, Everyuth, Nutralite and ActiLife. The
Company's shares are listed on the National Stock Exchange of India Limited
[NSE] and Bombay Stock Exchange Limited [BSE]. The Registered Office of the
company is situated at Zydus Tower, Satellite Cross Roads, Sarkhej-Gandhinagar
Highway, Ahmedabad-380015.
CONTINGENT
LIABILITIES
|
Particulars |
31.03.2013 |
31.03.2012 |
|
|
|
|
|
Claims against the company not acknowledged as debt. |
2.000 |
2.000 |
|
|
|
|
|
Other Money for which the company is contingently liable: |
|
|
|
- In respect of sales tax matters pending before appellate authorities |
11.900 |
5.500 |
|
- In respect of Income Tax matters pending before appellate authorities. |
0.400 |
16.500 |
|
|
|
|
|
In respect of guarantees given by Banks and/ Or Counter Guarantee given by the company. |
0.200 |
0.200 |
INDEX OF CHARGES: NO CHARGES EXIST FOR COMPANY
FIXED ASSETS:
· Freehold Land
· Leasehold Land
· Building
· Plant and Equipments
· Furniture and Fixtures
· Vehicles
· Office Equipments
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws, regulations
or policies that prohibit, restrict or otherwise affect the terms and
conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.80 |
|
|
1 |
Rs.91.95 |
|
Euro |
1 |
Rs.80.37 |
INFORMATION DETAILS
|
Information
Gathered by : |
SVA |
|
|
|
|
Report Prepared
by : |
NIT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
4 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
8 |
|
--LIQUIDITY |
1~10 |
8 |
|
--LEVERAGE |
1~10 |
8 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
8 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
YES |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
63 |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.